UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

     

FORM 8-K

   

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) :   February 12, 2018

     

Kadmon Holdings , Inc.

(Exact name of registrant as specified in its charter)

   

 

 

 

 

 

 

 

 

 

 

Delaware

 

001- 37841

 

27 - 3576929

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

450 East 29 th Street

New  York, NY

 

10016

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code ( 212 ) 3 08 - 6000

N/A

(Former name or former address, if changed since last report)

   



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):





 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended   transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



 


 

Item   8 .0 1

Other Events .



On February 12, 2018, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing initial results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2)   inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.  The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.







 

Item 9.01

Financial Statements and Exhibits.



(d) Exhibits   





 

Exhibit No.

Description

99.1

Press r elease, dated  February 12, 2018 , issued by Kadmon Holdings, Inc.




 



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 



 

 

 

 

 

 

 

 

 

 

 

 

 

Kadmon Holdings, Inc.

 

 

 

Date: February 12, 2018

 

 

 

/s/ Konstantin Poukalov

 

 

 

 

Konstantin Poukalov

 

 

 

 

Executive Vice President, Chief Financial Officer




Kadmon (NYSE:KDMN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kadmon Charts.
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kadmon Charts.